Novartis Investigative Site

Coventry CV6 4DD

2 studies enrolling now · 11 studies all time

What they study most

Acute Gout, Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Chronic Plaque Type Psoriasis, Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Oligometastatic Prostate Cancer (OMPC), Prostatic Neoplasms, Secondary Progressive Multiple Sclerosis (SPMS)

Studies at this site

• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer — Running, not enrolling
• Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients — Completed
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
• Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients — Completed